Effects of CYP2D6 polymorphisms on neuroleptic malignant syndrome

European Journal of Clinical Pharmacology

Volumn 63, Issue 11, 2007, Pages 991-996

  Kato, Daiji ^a   Kawanishi, Chiaki ^a   Kishida, Ikuko ^a   Furuno, Taku ^a   Suzuki, Kyoko ^a   Onishi, Hideki ^b   Hirayasu, Yoshio ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b SAITAMA MEDICAL UNIVERSITY HOSPITAL   (Japan)

Author keywords

Adverse reaction; CYP2D6; Gene deletion; Neuroleptic malignant syndrome; Polymorphism

Indexed keywords

AMITRIPTYLINE; AMOXAPINE; BIPERIDEN; BROMOCRIPTINE; BROMPERIDOL; CHLORPROMAZINE; CLOSPIPRAMINE; CYTOCHROME P450 2D6; EMONAPRIDE; FLUPHENAZINE; HALOPERIDOL; LEVOMEPROMAZINE; LITHIUM CARBONATE; MIANSERIN; PEROSPIRONE; QUETIAPINE; RISPERIDONE; SULPIRIDE; SULTOPRIDE; THIORIDAZINE; TIAPRIDE; ZOTEPINE;

ADULT; AGED; ALLELE; ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; FEMALE; GENE DELETION; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN CELL; JAPANESE; MAJOR CLINICAL STUDY; MALE; NEUROLEPTIC MALIGNANT SYNDROME; PHARMACOGENOMICS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ADOLESCENT; ADULT; AGED; ALLELES; ANTIPSYCHOTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; CHILD; CYTOCHROME P-450 CYP2D6; FEMALE; GENE DELETION; GENOTYPE; HUMANS; JAPAN; MALE; MIDDLE AGED; NEUROLEPTIC MALIGNANT SYNDROME; ODDS RATIO; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PREVALENCE; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 35248858788     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-007-0355-8     Document Type: Article

References (38)

1. Kawanishi C (2006) Pharmacogenetic aspects of neuroleptic malignant syndrome. Curr Pharmacogenomics 4:113-119
2. Caroff SN, Mann SC (1993) Neuroleptic malignant syndrome. Med Clin North Am 77:185-202
3. Ananth J, Parameswaran S, Gunatilake S, Burgoyne K, and Sidhom T (2004) Neuroleptic malignant syndrome and atypical antipsychotic drugs. J Clin Psychiatry 65:464-470
4. Caroff SN, Mann SC, Campbell EC (2000) Atypical antipsychotics and neuroleptic malignant syndrome. Psychiatric Annals 30:314-321
5. Ananth J, Parameswaran S, Gunatilake S, Burgoyne K, Sidhom T (2004) Neuroleptic malignant syndrome and atypical antipsychotic drugs. J Clin Psychiatry 65:464-470
6. Bertilsson L, Dahl ML, Dalen P, Al-Shurbaji A (2002) Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol 53:111-122
7. Kawanishi C, Furuno T, Onishi H, Sugiyama N, Suzuki K, Matsumura T, Ishigami T, Kosaka K (2000) Lack of association in Japanese patients between neuroleptic malignant syndrome and a debrisoquine 4-hydroxylase genotype with low enzyme activity. Psychiat Genet 10:145-147
8. Nishida Y, Fukuda T, Yamamoto I, Azuma J (2000) CYP2D6 genotypes in a Japanese population: low frequencies of CYP2D6 gene duplication but high frequency of*10. Pharmacogenetics 10:567-570
9. Scordo MG, Spina E (2002) Cytochrome P450 polymorphisms and response to antipsychotic therapy. Pharmacogenomics 3:201-218
10. Iwahashi K (1994) CYP2D6 genotype and possible susceptibility to the neuroleptic malignant syndrome. Biol Psychiatry 36:780-782
11. Kawanishi C, Shimoda Y, Fujimaki J, Onishi H, Suzuki K, Hanihara T, Sugiyama N, Kosaka K (1998) Mutation involving cytochrome P450IID6 in two Japanese patients with neuroleptic malignant syndrome. J Neurol Sci 160:102-104
12. Kato D, Kawanishi C, Kishida I, Furuno T, Matsumura T, Hasegawa H, Suzuki K, Hirayasu Y (2005) CYP2D6 gene deletion allele in patients with neuroleptic malignant syndrome: Preliminary report. Psychiatry Clin Neurosci 59:504-507
13. Pope GH, Keck PE, McElroy SL (1986) Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital. Am J Psychiatry 143:1227-1233
14. Kawanishi C, Hanihara T, Maruyama Y, Matsumura T, Onishi H, Inoue K, Sugiyama N, Suzuki K, Yamada Y, Kosaka K (1997) Neuroleptic malignant syndrome and hydroxylase gene mutations: No association with CYP2D6A or CYP2D6B. Psychiatr Genet 7:127-129
15. Wang SL, Huang JD, Lai MD, Liu BH, Lai ML (1993) Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: Polymorphism in RFLP and DNA sequence of CYP2D6. Clin Pharmacol Ther 53:410-418
16. Lundqvist E, Johanson I, Ingelman-Sundberg M (1999) Genetic mechanisms for duplication and multiduplication of the human CYP2D6 gene and method for detection of duplicated CYP2D6 genes. Gene 226:327-338
17. Johansson I, Lundqvist E, Dahl ML, Ingelman-Sundberg M (1996) PCR-based genotyping for duplicated and deleted CYP2D6 genes. Pharmacogenetics 6:351-355
18. Wennerholm A, Johansson I, Massele AY, Jande M, Alm C, Aden-Abdi Y, Dahl ML, Ingelman-Sundberg M, Bertilsson L, Gustafsson L (1999) Decreased capacity for debrisoquine metabolism among black Tanzanians: analysis of the CYP2D6 genotype and phenotype. Pharmacogenetics 9:707-714
19. Itoh H, Ohtsuka N, Ogita K, Yagi G, Miura S, Koga Y (1977) Malignant neuroleptic syndrome: its present status in Japan and clinical problems. Folia Psychiatr Neurol Jpn 31:565-576
20. Keck PE Jr, Pope HG Jr, Cohen BM, McElroy SL, Nierenberg AA (1989) Risk factors for neuroleptic malignant syndrome: a case-control study. Arch Gen Psychiatry 46:914-918
21. Sachdev P, Mason C, Hadzi-Pavlovic D (1997) Case-control study of neuroleptic malignant syndrome. Am J Psychiatry 154:1156-1158
22. Berardi D, Amore M, Keck PE Jr, Troia M, Dell'Atti M (1998) Clinical and pharmacologic risk factors for neuroleptic malignant syndrome: a case-control study. Biol Psychiatry 44:748-754
23. Caroff SN, Mann SC, McCarthy M, Naser J, Rynn M, Morrison M (1998) Acute infectious encephalitis complicated by neuroleptic malignant syndrome. J Clin Psychopharmacol 18:349-351
24. Deuschl G, Oepen G, Hermle L (1987) Neuroleptic malignant syndrome: observations on altered consciousness. Pharmacopsychiatry 20:168-170
25. Otani K, Horiuchi M, Kondo T, Kaneko S, Fukushima Y (1997) Is the predisposition to neuroleptic malignant syndrome genetically transmitted? Br J Psychiatry 41:1222-1224
26. Caroff SN, Mann SC (1998) Neuroleptic malignant syndrome. Psychopharmacol Bull 24:25-29
27. Wells AJ, SommiRW, Crismon L (1988) Neuroleptic malignant syndrome: case report and literature review. Drug Intell Clin Pharm 22:475-480
28. Lazarus AL, Moore KE, Spinner NB (1991) Recurrnt neuroleptic malignant syndrome associated with inv dup (15) and mental retardation. Clin Genet 39:65-67
29. Mahendran R, Winslow M, Lim D (2000) Recurrent neuroleptic malignant syndrome. Aust N Z J Psychiatry 34:699-700
30. Scordo MG, Spina E, Romeo P, Dahl ML, Bertilsson L, Johansson I, Sjoqvist F (2000) CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients. Eur J Clin Pharmacol 56:679-683
31. Ellingrod VL, Schultz SK, Arndt S (2000) Association between cytochrome P450 2D6 (CYP2D6) genotype, antipsychotic exposure, and abnormal involuntary movement scale (AIMS) score. Psychiatr Genet 10:9-11
32. Kapitany T, Meszaros K, Lenzinger E, Schindler SD, Barnas C, Fuchs K, Sieghart W, Aschauer HN, Kasper S (1998) Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia. Schizophr Res 32:101-106
33. Ohmori O, Suzuki T, Kojima H, Shinkai T, Terao T, Mita T, Abe K (1998) Tardive dyskinesia and debrisoquine 4-hydroxylase (CYP2D6) genotype in Japanese schizophrenics. Schizophr Res 32:107-113
34. Andreassen OA, MacEwan T, Gulbrandsen AK, McCreadie RG, Steen VM (1997) Non-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patients. Psychopharmacology 131:174-179
35. Kubota T, Yamaura Y, Ohkawa N, Hara H, Chiba K (2000) Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes. Br J Clin Pharmacol 50:31-34
36. Mihara K, Kondo T, Yasui-Furukori N, Suzuki A, Ishida M, Ono S, Kubota T, Iga T, Takarada Y, Vries R, Kaneko S (2003) Effects of various CYP2D6 genotypes on the steady-state plasma concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone, in Japanese patients with schizophrenia. Ther Drug Monit 25:287-293
37. Someya T, Shimoda K, Suzuki Y, Sato S, Kawashima Y, Hirokane G, Morita S, Yokono A, Takahashi S (2003) Effect of CYP2D6 genotypes on the metabolism of haloperidol in a Japanese psychiatric population. Neuropsychopharmacol 28:1501-1505
38. Kishida I, Kawanishi C, Furuno T, Kato D, Ishigami T, Kosaka K (2004) Association in Japanese patients between neuroleptic malignant syndrome and functional polymorphisms of the dopamine D(2) receptor gene. Mol Psychiatry 9:293-298